Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06758596

Research Investigating Drug Effects-2 (RiDE-2)

The purpose of this study is to better understand how people's mood, behavior, and brains respond to different recreational drugs. We are also trying to understand why some people may feel differently or their brain may respond differently than other people after taking the same recreational drug.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–21 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

University of Illinois at Chicago

Chicago, Illinois, 60612, United States

Location contact

Natania Crane, PhD

CONTACT

[email protected]

312-413-4453

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age 18-21 at eligibility visit
  • body mass index of 18.5-30
  • report using cannabis ≥10 times in their life and ≥1 time in the past 3 months, but <7 days a week (daily)
  • medically and neurologically healthy
  • score of ≥0.25 on the Personality Inventory for DSM-5 (PID-5) Anhedonia subscale

Exclusion criteria

  • positive urine drug screen (UDS; except for THC) and/or positive saliva THC test
  • contraindication for fMRI BOLD study (e.g., metal implants)
  • severe mental illness (e.g., psychosis, mania, lifetime moderate-to-severe SUD (including moderate-to-severe CUD))
  • heavy nicotine use in the past month (>20 cigarettes per week or electronic nicotine delivery system (ENDS) use equivalent
  • night shift work
  • females who are currently pregnant confirmed by urine pregnancy test, are planning pregnancy, or are lactating
  • unwilling/unable to sign informed consent document
  • current or past allergic or adverse reaction or known sensitivity to cannabinoid-like substances (Dronabinol/Marijuana/Cannabis/THC, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide)
  • physical or neurological diagnoses (e.g., cancer, diabetes, seizure disorder, Parkinson's, Multiple Sclerosis, loss of consciousness >10 min., etc.) that in the opinion of the Study Physician and Investigators could increase safety risks or influence the findings
  • currently taking any medication that could interact with a single dose of Δ9-THC

Treatment and study plan

Placebo oral capsule

Drug

A capsule that contains only dextrose filler administered during the first or second laboratory visit.

THC

Drug

A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit.

Primary outcomes

  1. Recent Substance Use

    Time frame: Baseline screening, baseline drug administration, and every 6 months over two years of follow-up

    Participants will complete the 6-month Timeline Follow-Back (TLFB) and Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory (DFAQ-CU) to assess recent substance use. This measure will capture the frequency of substance use during the past 6 months, with greater values indicating more frequent substance use.

  2. CUD/SUD Symptoms

    Time frame: Baseline screening and yearly over the two-year follow-up.

    Participants will complete the SCID CUD diagnosis and symptom assessment at baseline screening and yearly follow-ups to evaluate the presence and severity of cannabis use disorder (CUD) and other substance use disorder (SUD) symptoms.

  3. Neural Reward Anticipation - fMRI response to reward anticipation (MID)

    Time frame: First and second laboratory visits, around 90 minutes to 2 hours after drug administration.

    Participants will complete the Monetary Incentive Delay (MID) task during fMRI scanning to assess neural activation related to reward anticipation. Greater activation in reward-related brain regions (e.g., striatum, prefrontal cortex) indicates greater neural sensitivity to anticipated rewards and the impact of THC on reward processing.

  4. Computationally-Derived Behavioral Reward Learning Rate - Learning rate (alpha parameter)

    Time frame: First and second laboratory visits, around 90 minutes to 2 hours after drug administration.

    Participants will complete the Bandit task during fMRI scanning. A behavioral measure of learning rate (alpha parameter) will be derived from computational models based on the Rescorla-Wagner (RW) model, with higher learning rates indicating greater learning and adaptation to reward contingencies.

  5. Computationally-Derived Behavioral Reward Sensitivity - Reward sensitivity (inverse temperature parameter)

    Time frame: First and second laboratory visits, around 90 minutes to 2 hours after drug administration.

    Participants will complete the Bandit task during fMRI scanning, and a behavioral measure of reward sensitivity will be derived from the Rescorla-Wagner (RW) model. Greater values indicate higher sensitivity to rewards and a stronger preference for rewarding outcomes.

  6. Neural Encoding of Reward Prediction Errors - fMRI response to reward prediction errors (Bandit Task)

    Time frame: First and second laboratory visits, around 90 minutes to 2 hours after drug administration.

    Participants will complete the Bandit task during fMRI scanning. fMRI analysis will focus on trial-wise neural encoding of prediction errors, with greater activation indicating more salient reward learning signals in response to prediction errors, reflecting how the brain processes unexpected outcomes during reward learning.

Study contacts

Contact information is provided by the study sponsor or research team.

Natania Crane, PhD

CONTACT

[email protected]

(312) 413-4453

Sponsors and collaborators

Lead sponsor

University of Illinois at Chicago

Other

Registry information

Acronym: RiDE-2

Important dates

Study start
2026
Primary completion
2031
Study completion
2031
First posted
Jan 6, 2025
Registry last updated
Sep 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.